EGFR mutant-selective inhibitor NX-019

{
  "id": "MLC-T-ONC-013259",
  "term": "EGFR mutant-selective inhibitor NX-019",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, central nervous system (CNS)-penetrating, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor NX-019 targets, binds to, and inhibits the activity of EGFR mutations, including exon 19 deletions, L858R, T790M, exon 20 insertions, and certain other mutations, thereby preventing EGFR-mediated signaling, which induces cell death and inhibits tumor growth in EGFR mutant-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. NX-019 is selective for mutant EGFR over wild-type EGFR.",
  "synonyms": [
    "EGFR inhibitor NX-019"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-mutant-selective-inhibitor-nx-019/"
}